A Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine Therapy

NCT07071337 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

430

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Breast Cancer

Interventions

DRUG: SKB264
DRUG: Nab-paclitaxel
DRUG: Paclitaxel
DRUG: Capecitabine

Sponsor

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.